坎伯兰药业 CPIX 深 沪
等待开盘 08-14 09:30:00 美东时间
2.91
0.000
0.00%
华盛通- 最 高2.995
- 今 开2.96
- 成交量 4.04万股
- 最 低 2.85
- 昨 收 2.91
- 总市值 4353.68万
- 52周最高 7.25
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.04
- 委 比 11.11%
- 总股本 1496.11万
- 历史最高 8.02
- 量 比 0.34
- 振 幅 4.98%
- 历史最低 1.04
- 每 手 1
- 风险率 1.65%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cumberland Pharmaceuticals reports Q2 results
Cumberland Pharmaceuticals press release (NASDAQ:CPIX): Q2 GAAP EPS of -$0.05 Revenue of $10.8M (+9.1% Y/Y). More on Cumberland Pharmaceuticals Cumberland Pharmaceuticals Inc. (CPIX) Q2 2025 Earnings ...
08-06 14:40
Cumberland Q2 Adj. EPS $0.18 Up From $0.01 YoY, Sales $10.800M Up From $9.849M YoY
Cumberland (NASDAQ:CPIX) reported quarterly earnings of $0.18 per share. This is a 1700 percent increase over earnings of $0.01 per share from the same period last year. The company reported $10.800 million in sales
08-06 04:13
Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date
NASHVILLE, Tenn., Aug. 5, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved ...
08-06 04:05
Earnings Scheduled For August 5, 2025
Companies Reporting Before The Bell • Silicon Laboratories (NASDAQ:SLAB) is exp...
08-05 16:32
Cumberland Pharma Announces Availability Of Vibativ 4-Vial Starter Pak Through New Contract With Vizient
Vizient serves more than 65% of the nation's acute care providers, including 97% of academic medical centersNASHVILLE, Tenn., Aug. 4, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty
08-04 21:06
CUMBERLAND PHARMACEUTICALS RECEIVES VIZIENT CONTRACT FOR NEW VIBATIV® 4-VIAL STARTER PAK
Vizient serves more than 65% of the nation's acute care providers, including 97% of academic medical centers NASHVILLE, Tenn., Aug. 4, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (N...
08-04 21:05
Cumberland Pharma Presents Latest Results From Phase 2 FIGHT DMD Trial Evaluating Ifetroban, Oral Therapy For DMD Heart Disease, At PPMD Conference In Las Vegas
New pharmacokinetic and cardiac biomarker data further demonstrate ifetroban's potential to protect the heart and reduce cardiac damage in DMD patientsNASHVILLE, Tenn., June 23, 2025 /PRNewswire/ -- Cumberland
06-23 21:09
Cumberland Pharmaceuticals shares are trading higher after the company announced it published a study investigating Caldolor in older patients.
Cumberland Pharmaceuticals shares are trading higher after the company announce...
05-29 01:18
Cumberland Pharmaceuticals And Qureight Partner To Advance Idiopathic Pulmonary Fibrosis Treatment Research
Cumberland leveraging Qureight's deep-learning AI platform for its Phase II FIGHTING FIBROSIS™ clinical trial
05-14 04:17
CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH
Cumberland leveraging Qureight's deep-learning AI platform for its Phase II FIGHTING FIBROSIS™ clinical trial NASHVILLE, Tenn. and CAMBRIDGE, England, May 13, 2025 /PRNewswire/ -- Cumberlan...
05-14 04:05
